XML 40 R27.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration and Licensing Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Collaboration and Licensing Agreements |
Schedule of revenue by licensees | The $40.6 million, $46.2 million and $109.0 million of revenue recorded for the years ended December 31, 2018, 2017 and 2016, respectively, was earned principally from the following licensees (in millions):
|  | Year Ended |
|  | December 31, |
|  | 2018 |  | 2017 |  | 2016 |
|  |  |  | (As Revised) |  | (As Revised) |
Amgen |  | $ | 0.6 |  | $ | 10.0 |  | $ | 31.2 |
Alexion |  |  | 20.0 |  |  | — |  |  | 5.0 |
CSL |  |  | — |  |  | 3.5 |  |  | — |
MorphoSys |  |  | — |  |  | 12.5 |  |  | — |
Novo Nordisk |  |  | — |  |  | — |  |  | 2.7 |
Novartis |  |  | 20.0 |  |  | 20.1 |  |  | 69.9 |
Other |  |  | — |  |  | 0.1 |  |  | 0.2 |
Total |  | $ | 40.6 |  | $ | 46.2 |  | $ | 109.0 |
Schedule of disaggregation of revenue | The below table summarizes the disaggregation of revenue recorded for the years ended December 31, 2018, 2017 and 2016 (in millions):
|  | Year Ended
|  | December 31,
|  | 2018 |  | 2017 |  | 2016
|  |  |  | (As Revised) |  | (As Revised)
Research collaboration |  | $ | 20.1 |  | $ | 20.1 |  | $ | 34.2
Milestone |  |  | 20.5 |  |  | 26.0 |  |  | 5.0
Licensing |  |  | — |  |  | 0.1 |  |  | 69.8
Total |  | $ | 40.6 |  | $ | 46.2 |  | $ | 109.0
Schedule of revenue from U.S. and Non U.S. sources | A breakdown of our revenue from U.S. and Non‑U.S. sources for the years ended December 31, 2018, 2017 and 2016 is as follows (in millions):
|  | Year Ended |
|  | December 31, |
|  | 2018 |  | 2017 |  | 2016 |
|  |  |  |  | (As Revised) |  | (As Revised) |
U.S. Revenue |  | $ | 40.6 |  | $ | 30.2 |  | $ | 106.3 |
Non-U.S. Revenue |  |  | — |  |  | 16.0 |  |  | 2.7 |
Total |  | $ | 40.6 |  | $ | 46.2 |  | $ | 109.0 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | xncr_CollaborationResearchAndLicensingAgreementsDisclosureAbstract
Namespace Prefix: | xncr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue by major licensees. + References No definition available. + Details
Name: | xncr_ScheduleOfRevenueByMajorLicenseesTableTextBlock
Namespace Prefix: | xncr_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration